Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma
Recent Articles
FDA Deputy Commissioner and CIO Amy Abernethy Resigns
Amy Abernethy, MD, PhD, has announced that she plans to resign from her roles as principal deputy commissioner and acting chief information officer at...
FDA Approves Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell...
AstraZeneca COVID-19 Vaccine Data Highlight Safety Monitoring Boards’ Role in Clinical Trials
Confusion over AstraZeneca’s COVID-19 vaccine trial data recently arose when the data and safety monitoring boards (DSMBs) overseeing the trial took a public stand...
Does Elotuzumab Improve PFS in High-Risk Myeloma?
The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously...
How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?
Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.